These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 15995268)

  • 21. [Visceral leishmaniasis: new drugs].
    Minodier P; Robert S; Retornaz K; Garnier JM
    Arch Pediatr; 2003 Dec; 10 Suppl 5():550s-556s. PubMed ID: 15022780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kala-azar in Bihar.
    Prasad LS
    Indian J Pediatr; 1987; 54(1):103-10. PubMed ID: 3030932
    [No Abstract]   [Full Text] [Related]  

  • 23. Current diagnosis and treatment of visceral leishmaniasis.
    Mondal S; Bhattacharya P; Ali N
    Expert Rev Anti Infect Ther; 2010 Aug; 8(8):919-44. PubMed ID: 20695748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct immunity in patients with visceral leishmaniasis from that in subclinically infected and drug-cured people: implications for the mechanism underlying drug cure.
    Hailu A; Menon JN; Berhe N; Gedamu L; Hassard TH; Kager PA; Olobo J; Bretscher PA
    J Infect Dis; 2001 Jul; 184(1):112-5. PubMed ID: 11398119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolation of Leishmania tropica from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran.
    Alborzi A; Pouladfar GR; Fakhar M; Motazedian MH; Hatam GR; Kadivar MR
    Am J Trop Med Hyg; 2008 Sep; 79(3):435-7. PubMed ID: 18784238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti leishmanial therapy--the changing scene.
    Bichile LS
    J Assoc Physicians India; 1994 Sep; 42(9):682-3. PubMed ID: 7883657
    [No Abstract]   [Full Text] [Related]  

  • 27. Successful use of miltefosine and sodium stibogluconate, in combination, for the treatment of an HIV-positive patient with visceral leishmaniasis: a case report and brief review of the literature.
    Collini P; Premchand N; Lockwood D; Greig J
    Ann Trop Med Parasitol; 2009 Jul; 103(5):455-9. PubMed ID: 19583915
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of aminosidine (paromomycin) and sodium stibogluconate for treatment of canine leishmaniasis.
    Poli A; Sozzi S; Guidi G; Bandinelli P; Mancianti F
    Vet Parasitol; 1997 Aug; 71(4):263-71. PubMed ID: 9299695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of visceral leishmaniasis or kala-azar (author's transl)].
    Laroche R; Sirol J; Poli L
    Med Trop (Mars); 1978; 38(4):401-4. PubMed ID: 215868
    [No Abstract]   [Full Text] [Related]  

  • 30. Serial use of pentamidine and miltefosine for treating Leishmania infantum-HIV coinfection.
    Faucher JF; Morquin D; Reynes J; Chirouze C; Hoen B; Le Moing V
    Parasitol Int; 2016 Oct; 65(5 Pt A):444-6. PubMed ID: 27353022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.
    Guffanti M; Gaiera G; Bossolasco S; Ceserani N; Ratti D; Cinque P; Salmaso F; Gianotti N; Lazzarin A
    Am J Trop Med Hyg; 2008 Nov; 79(5):715-8. PubMed ID: 18981510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
    Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
    J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of localized cutaneous leishmaniasis].
    Buffet P; Caumes E; Gentilini M
    Ann Dermatol Venereol; 1994; 121(6-7):503-11. PubMed ID: 7702288
    [No Abstract]   [Full Text] [Related]  

  • 34. Eliminating visceral leishmaniasis in South Asia: the road ahead.
    Rijal S; Sundar S; Mondal D; Das P; Alvar J; Boelaert M
    BMJ; 2019 Jan; 364():k5224. PubMed ID: 30670453
    [No Abstract]   [Full Text] [Related]  

  • 35. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.
    Olliaro P; Sundar S
    Trop Med Int Health; 2009 Jan; 14(1):88-92. PubMed ID: 19121150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cutaneous leishmaniasis treatment.
    Minodier P; Parola P
    Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium antimony gluconate, amphotericin, and myocardial damage.
    Thakur CP
    Lancet; 1998 Jun; 351(9120):1928-9. PubMed ID: 9654264
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of visceral leishmaniasis: options and choice.
    Bhattacharya SK; Dash AP
    Lancet Infect Dis; 2016 Feb; 16(2):142-3. PubMed ID: 26867454
    [No Abstract]   [Full Text] [Related]  

  • 39. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.
    Wasan KM; Wasan EK; Gershkovich P; Zhu X; Tidwell RR; Werbovetz KA; Clement JG; Thornton SJ
    J Infect Dis; 2009 Aug; 200(3):357-60. PubMed ID: 19545212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.